Neoantigens can be differentially recognized by T cell receptor (TCR) as these 31 sequences are derived from mutant proteins and are unique to the tumor. The 32 discovery of neoantigens is the first key step for tumor-specific antigen (TSA) based 33 immunotherapy. Based on high-throughput tumor genomic analysis, each missense 34 mutation can potentially give rise to multiple neopeptides, resulting in a vast total 35 number, but only a small percentage of these peptides may achieve immune-dominant 36 status with a given major histocompatibility complex (MHC) class I allele. Specific 37 identification of immunogenic candidate neoantigens is consequently a major 38 challenge. Currently almost all neoantigen prediction tools are based on genomics 39 data. Here we report the construction of proteogenomics prediction of neoantigen 40 (ProGeo-neo) pipeline, which incorporates the following modules: mining tumor 41 specific antigens from next-generation sequencing genomic and mRNA expression 42 data, predicting the binding mutant peptides to class I MHC molecules by latest 43 netMHCpan (v.4.0), verifying MHC-peptides by MaxQuant with mass spectrometry 44 proteomics data searched against customized protein database, and checking potential 45 immunogenicity of T-cell-recognization by additional screening methods. ProGeo-neo 46 pipeline achieves proteogenomics strategy and the neopeptides identified were of 47 much higher quality as compared to those identified using genomic data only. The 48 pipeline was constructed based on the genomics and proteomics data of Jurkat 49 leukemia cell line but is generally applicable to other solid cancer research. With 50 massively parallel sequencing and proteomics profiling increasing, this 51 proteogenomics workflow should be useful for neoantigen oriented research and 52 immunotherapy.
5
The ProGeo-neo workflow construction is illustrated in Figure 1 
Mutation annotation and peptide extraction 178
Tumor missense mutations, translated into amino acid substitutions, provide a form of 179 antigens that the immune system perceives as foreign, which elicits tumor-specific T 180 cell immunity. Hence, we focused on missense variants in this study. All the mutations 181 were annotated with Annovar. Sequences corresponding to each of the coding 182 missense mutations that would cause amino-acid substitutions were translated into a 
Classification of neoantigen prediction result 186
Percentile rank scores return a higher sensitivity in MHC ligand identification 187 compared to half-maximum inhibitory Concentration (IC50) [32], the rank score 188 8 approach starts from the extreme assumption that the number of presented peptides is 189 identical for all MHC molecules, this measure is not affected by inherent bias of 190 certain molecules towards higher or lower mean predicted affinities. We therefore 191 select candidate binders based on %Rank rather than IC50, the smaller of %rank value 192 indicates the stronger affinity of the predicted neoantigen with its corresponding HLA 193 subtype. Each peptide may be classified as a strong binder (%Rank≤0.5), weak binder 194 (0.5<%Rank≤2) or non-binder (%Rank>2). We included both strong and weak 195 binding predicted neoantigens in sebsequent analyses. 203 SNVs from RNA-seq data provide a better reference proteomics datasets compared 204 with WGS, of which the read coverage is generally lower [33] . Therefore, mass Supplementary Table S1 ). were used for subsequent analysis, which is a phred-scaled score that reflects the 281 confidence of the SNV call. Eventually, high-quality non-synonymous missense 282 mutations were identified. For each missense mutation, a custom Python script was 283 12 used to translate the reference amino acid to the variant amino acid and totally 284 generated 9,083 mutant protein sequences. Using these mutant protein sequences, 285 along with the human reference proteome (Human 21,410 entries) and cRAP (Human 286 68 entries), a customized fasta database was created.
Identification of mutant peptides in protein level

287
The customized database was searched against the MS data using the MaxQuant 288 software with described parameters. 70,622 peptides were identified at a 1% FDR.
289
From these, there were a total of 487 mutant peptides (7-43AA) mapping to 473 290 missense SNV sites ( Supplementary Table S2 ), corresponding to 0.69% of all peptides. 
Filtering neoantigens potentially recognized by T cell receptors 298
Peptides of bacterial and viral pathogens can be recognized by immunogenic T cells, 299 therefore neoantigens cross-reactive with these extrogenous pathogens may be 300 recognized by tumor reactive T cells. Among the 655 candidate neoantigens, 313 301 neoantigens were found to be most likely recognized by the TCR repertoir based on a 302 sequence comparison analysis ( Supplementary Table S3 ), with a comparison 303 probability of 47.79%. The results of sequence similarity between neoantigens and 304 cross-reactive peptides were ranged from 20 to 100. We artificially divided the 305 sequence similarity score of neoantigens into four stages (20-39, 40-59, 60-79, 80-100) 306 (Figure 3) , it is observed that the scores of sequence similarity are greater than 60 307 among the majority of neoantigens. Generally, the higher the sequence similarity, the 308 greater the likelihood that a neoantigen will be recognized by a T cell receptor.
309
To test if our method provides the accuracy to identify mutant peptides as neoantigens, 310 we performed the sequence similarity analysis of peptides that were not filtered by 311 mass spectrometry in the same way. It was found that 11,100 peptides have sequence 312 13 similarity with cross reactive microbial peptides among the 29,486 candidate 313 neoantigens, with a comparison probability of 37.64%, which was significantly lower 314 than our previous alignment probability 47.79%. It proves the validity of 315 identification at the protein level. 359 We have further implemented the proposed approach as an integrated software 360 named ProGeo-neo, which is written in Python programming language (v2.7), 361 and calls for standard third-party software. In order to run normally, third-party 362 softwares are provided, but Licenses for academically used software 363 (NetMHCpan) must be obtained by users. Compared with other neoantigen 364 prediction pipelines, ProGeo-neo has a number of advantages: first, it offers a 365 pipeline for mutation calling from high-throughput sequencing data; second, it 366 offers a proteogenomic strategy to build customized database derived from 367 tumor RNA-seq data; third, it not only takes into consideration the neoantigens 368 presented by class I MHC molecules, but also directly identifies these mutant 369 peptides with MS data; fourth, it offers additional filtration criteria: tumor vs. 370 closest microbial peptide sequence similarity.
371
The software consists of three toolkits: construction of customized protein 372 sequence database, HLA alleles prediction, neoantigen prediction and filtration.
373
Before running the toolkit, users need to configure the software paths and Figure 5B ), which will benefit preclinical studies. In our work, 9,871 mutant peptides 388 (21AA), which map to 5,482 genes, give rise to 373,046 theoretical mutant peptides.
389
About 10% potential HLA-I binding neoantigens were identified by NetMHCpan.
390
Tandem mass spectra were processed by MaxQuant to infer mutant peptides, only a 391 minority of them were verified at the level of proteome ( Figure 5B ). The neopeptides 392 identified from this customized database workflow were of much higher quality as 393 compared to those identified using genomic data without filtering. Finally, sequence 394 homology analysis was performed based on blastp algorithm, 313 neoantigens on 77 395 mutant proteins were identified. Furthermore, we found that the fraction of 396 neoantigens derived from driver genes were less than the number of neoantigens 397 expressed by passenger genes (Figure 4) , which was consistent with previous report to increase, and our pipeline ProGeo-neo would be a useful bioinformatics aid. 443 We are aware that our study bears several limitations. First, mutations in tumor 444 include not only point mutations but insertion/deletion mutations or frame shift 445 mutations. It is clear that insertion/deletion and frameshift mutation will lead to larger 446 changes in amino acid sequence and spatial structure, which may also generate 447 potential neoantigens, these genomic variations are not yet considered in current 
